XTLB: XTL Bio Price to Sales
XTL Biopharmaceuticals is developing therapies to combat autoimmune pathologies, banking on future pricing power. The market capitalization-to-revenue ratio confirms the market valuation, where the value of 12.70 serves as the current metric. The company is optimizing its immunological raw material supply chains to protect margins while simultaneously restructuring its asset portfolio through the integration of medical IT solutions and ready-made commercial developments.
XTL Biopharmaceuticals, Ltd. (XTLB) - metric breakdowns and financial figures
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- business debt structure and liquidity details:
Debt to Equity XTL Biopharmaceuticals|XTLB - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital XTL Bio|XTLB - Company Aggregate Debts|Debt to Book Capitalization Ratio XTL Biopharmaceuticals, Ltd.|XTLB - Company Long-Term Debts|Short-Term Debt Volume XTL Biopharmaceuticals|Immediate Liquidity xtlbio.com
- net income and valuation multiples indicators:
XTLB - Company Net Income|Forward Earnings XTL Biopharmaceuticals|XTLB - P/E Multiple|Future Price to Earnings Multiple XTL Biopharmaceuticals Ltd|XTLB - PEG Multiple|EV/EBITDA Multiple XTL Biopharmaceuticals, Ltd.|XTLB - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year XTL Biopharmaceuticals|XTLB - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months xtlbio.com|XTLB - Earnings growth in current year|Earnings growth forecast for next year XTL Biopharmaceuticals
- sales revenue and business income indicators:
General company analysis:xtlbio.com XTLB
Searching for assets with a high margin of safety begins with analyzing the market capitalization-to-revenue ratio. The P/S ratio measures the cost of each unit of sales, making it possible to identify overvalued expectations relative to actual cash flows. For XTL Biopharmaceuticals, the value of 12.70 reflects the efficiency of monetizing the distribution of bioactive substances while minimizing regulatory risks. The dynamics of this indicator within the price-to-sales multiplier history help determine the fair value point of the shares.
Competing companies
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA: Market Cap to Revenue|PTGX (Protagonist Corp) - Market Cap to Revenue Ratio|IMVT (Immunovant, Inc.) - Market Cap to Revenue|KNSA: Market Cap to Sales Volume|Price-to-Revenue Ratio Grifols|Price-to-Revenue Ratio ADPT|Market Cap to Revenue CLDX (Celldex)|AUPH (Aurinia Corp) - Market Capitalization-to-Revenue Ratio|P/S Multiple BCRX (BioCryst)|veratx.com - Price-to-Revenue Ratio|Dianthus Therapeutics, Inc. - P/S Multiple|Price-to-Revenue Coefficient Pharvaris NV PHVS|AbCellera Biologics Inc (ABCL) - Price-to-Revenue Ratio|Price to Sales Tourmaline (TRML)|Price-to-Revenue Ratio Precigen, Inc.|pharming.com - Price-to-Sales Ratio|P/S Multiple NKTR|UPB (Upstream Bio, Inc.) - Market Capitalization-to-Revenue Ratio|P/S Multiple ZBIO (Zenas Biopharma, Inc.)|P/S Multiple Immunome Bio IMNM|GOSS - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio KALV (kalvista.com)|Septerna (SEPN) - Price-to-Revenue Ratio|Market Cap to Revenue Pieris Pharma|SVRA (Savara Corp) - P/S Multiple|P/S Multiple Rigel Corp|P/S Multiple ANAB|Market Cap to Revenue astriatx.com ATXS|P/S Multiple ENGN (enGene)|RAPT Therapeutics Inc. (RAPT) - Price to Sales|JBIO: Market Cap to Revenue|ACRS - P/S Multiple|KYTX (Kyverna Therapeutics) - Market Cap to Revenue|TLSA: Market Cap to Sales Volume|CABA (Cabaletta Bio) - P/S Multiple|Ventyx Biosciences Inc. (VTYX) - Price-to-Revenue Coefficient|P/S Multiple THTX|Market Cap to Revenue Avalo Therapeutics Inc AVTX|P/S Multiple ELDN (Eledon Pharmaceuticals)|P/S Multiple agenusbio.com AGEN|CLYM - Price-to-Revenue Ratio|ZURA: Price-to-Revenue Ratio|aTyr (ATYR) - Price-to-Revenue Ratio|ADAG - Price-to-Revenue Coefficient|Market Cap to Revenue IMA|Market Cap to Revenue Ratio STTK (Shattuck Therapeutics)|Market Cap to Revenue EQ (Equillium, Inc.)|Market Cap to Sales Volume CNTB|Price-to-Revenue Ratio Immunic IMUX|Atara Biotherapeutics, Inc. - Price-to-Revenue Ratio|InflaRx GmbH - P/S Multiple|XFOR: Price-to-Revenue Ratio|adicetbio.com (ACET) - Price-to-Revenue Ratio|Price-to-Sales Ratio CELU (Celularity)|INMB (INmune Bio Corp) - P/S Multiple|BRNS: Market Capitalization-to-Revenue Ratio|P/S Multiple KZR|P/S Multiple sabbiotherapeutics.com (SABS)|Price-to-Revenue Ratio Akari Therapeutics Plc AKTX|Market Capitalization-to-Revenue Ratio ENLV|QTTB - Price-to-Revenue Ratio|GeoVax Corp (GOVX) - Market Cap to Revenue|EDSA: P/S Multiple|ibioinc.com (IBIO) - P/S Multiple|Market Cap to Revenue CARM|BOLT: Market Capitalization-to-Revenue Ratio|P/S Multiple HCWB|Price-to-Revenue Coefficient aptevotherapeutics.com|Price-to-Revenue Ratio AIM ImmunoTech Inc. AIM|ADTX - Market Cap to Revenue|GRI - Price-to-Revenue Ratio|XORTX Therapeutics Inc (XRTX) - Market Cap to Revenue|HIND (ReShape Lifesciences) - Market Cap to Revenue|Revelation Biosciences Corp (REVB) - P/S Multiple|Price-to-Revenue Ratio Indaptus Therapeutics|Market Cap to Revenue Ratio SCNI (scinai.com)|P/S Multiple CALI|AFMD - Price to Sales|Allakos - Market Cap to Revenue|HOOK: Market Cap to Revenue Ratio|IGMS: Market Cap to Revenue|iteostherapeutics.com - Market Cap to Sales Volume|Ocean Biomedical (OCEA) - Price-to-Revenue Ratio|TCBP (TC BioPharm (Holdings) Plc) - Price-to-Revenue Ratio|Market Cap to Revenue THRD
